시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 비인두암 치료 시장 보고서(2025년)
Nasopharyngeal Carcinoma Treatment Global Market Report 2025
상품코드 : 1693342
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,156,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,898,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,640,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비인두암 치료 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년까지 6.9%의 연평균 성장률(CAGR)로 16억 9,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 새로운 표적 치료, 맞춤형 의료 접근법, 치료 접근성의 세계 확대, 성공적인 임상시험, 조기 발견에 대한 지속적인 집중에 기인합니다. 예측 기간의 주요 동향으로는 병용요법의 도입, 지지요법과 삶의 질에 대한 강조, 치료 계획에 인공지능(AI)의 통합, 임상시험 및 연구 이니셔티브의 확대, 조기 발견을 위한 영상 기술 강화 등이 있습니다.

비인두암 치료 시장은 담배 소비량 증가로 인해 성장할 것으로 예상됩니다. 담배는 담배 잎을 말린 것으로, 일반적으로 흡연이나 씹는 데 사용되며 다양한 담배 제품의 주요 성분으로 사용됩니다. 담배 사용의 증가는 비인두암 발병 위험을 증가시켜 수술, 방사선 치료, 화학요법, 표적 치료와 같은 효과적인 치료 옵션을 필요로 합니다. 캐나다 통계청의 보고에 따르면 2023년 7월 캐나다의 담배 생산량은 6월에 비해 2.2% 증가했고, 담배 판매량도 2.6% 증가하여 6월에 14억 개비에 달했다고 합니다. 따라서 담배 소비량의 증가가 비인두암 치료 시장의 확대를 주도하고 있습니다.

비인두암 치료 시장은 엡스타인-바 바이러스(EBV) 감염의 급증으로 인해 성장할 것으로 예상되며, EBV는 비인두암(NPC)과 밀접한 관련이 있는 헤르페스 바이러스과에 속하는 전염성이 강한 감염성 질환입니다. 이 바이러스는 주로 체액, 특히 타액을 통해 전파되며 NPC의 발병과 밀접한 관련이 있습니다. 미국 국립 의학 도서관은 2023년 8월 전 세계 성인 인구의 95%가 EBV에 노출되어 있다고 보고했습니다. 또한 미국에서는 소아 및 청소년의 EBV 유병률이 다양하며, 특정 연령대의 감염률은 약 54%, 18-19세 청소년의 감염률은 약 82.9%로 최고조에 달합니다. 결과적으로 EBV 감염률의 증가는 비인두암 치료 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

ksm
영문 목차

영문목차

Nasopharyngeal carcinoma (NPC) is a type of cancer that originates in the nasopharynx, the upper part of the throat located behind the nose. The treatment of nasopharyngeal carcinoma involves various medical interventions and therapies aimed at managing and combating cancerous growth in the nasopharynx, with goals such as achieving remission, managing symptoms, and improving the overall well-being of the patient.

The main types of nasopharyngeal carcinoma include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma. Non-keratinizing undifferentiated carcinoma is characterized by the absence of keratin, a protein typically found in the outer layers of the skin. Treatment for this type of carcinoma typically involves a combination of radiation therapy and chemotherapy. Chemotherapy drugs such as ellence, taxotere, bleomycin, and methotrexate are employed in various treatment modalities, including chemotherapy, immunotherapy, radiation therapy, and others. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The nasopharyngeal carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides nasopharyngeal carcinoma treatment market statistics, including nasopharyngeal carcinoma treatment industry global market size, regional shares, competitors with a nasopharyngeal carcinoma treatment market share, detailed nasopharyngeal carcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasopharyngeal carcinoma treatment industry. This nasopharyngeal carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nasopharyngeal carcinoma treatment market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to high prevalence in endemic regions, advancements in radiation therapy, improved diagnostic methods, awareness and screening programs, collaborative research initiatives.

The nasopharyngeal carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to emerging targeted therapies, personalized medicine approaches, global expansion of treatment access, clinical trial successes, continued focus on early detection. Major trends in the forecast period include implementation of combination therapies, focus on supportive care and quality of life, integration of artificial intelligence (ai) in treatment planning, expansion of clinical trials and research initiatives, enhanced imaging technologies for early detection.

The nasopharyngeal carcinoma treatment market is expected to witness growth propelled by the rise in tobacco consumption. Tobacco, derived from dried leaves of the tobacco plant, is commonly used for smoking or chewing and is a key component in various tobacco products. Increased tobacco use elevates the risk of developing nasopharyngeal carcinoma, necessitating effective treatment options such as surgery, radiation therapy, chemotherapy, and targeted therapies. Notably, Statistics Canada reported a 2.2% surge in cigarette production in Canada in July 2023 compared to June, coupled with a 2.6% increase in cigarette sales, reaching 1.4 billion units in June. Hence, the escalating tobacco consumption drives the expansion of the nasopharyngeal carcinoma treatment market.

The nasopharyngeal carcinoma treatment market is projected to grow due to an upsurge in Epstein-Barr virus (EBV) infections. EBV, a highly contagious infection belonging to the herpesvirus family, is closely linked to Nasopharyngeal Carcinoma (NPC). The virus spreads primarily through bodily fluids, notably saliva, and is strongly associated with NPC development. The National Library of Medicine reported a staggering 95% global adult population exposure to EBV in August 2023. Moreover, in the United States, EBV prevalence among children and adolescents varies, with infection rates around 54% in certain age groups and peaking at approximately 82.9% among adolescents aged 18 to 19. Consequently, the escalating incidence of EBV infections drives growth in the nasopharyngeal carcinoma treatment market.

Major players in the nasopharyngeal carcinoma treatment market are concentrating on developing advanced technological solutions, such as Loqtorzi, to meet various critical industry needs. Loqtorzi is an oral medication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that targets tumor growth while minimizing side effects. It can be utilized alongside other therapies to boost effectiveness. For example, in January 2024, Coherus BioSciences, a US-based biopharmaceutical firm, launched LOQTORZI (toripalimab-tpzi), the first FDA-approved treatment for nasopharyngeal carcinoma (NPC) applicable across all lines of therapy. This anti-PD-1 monoclonal antibody is indicated for use in conjunction with chemotherapy for first-line treatment and as a standalone therapy for patients who have progressed after platinum-based chemotherapy. Clinical trials have demonstrated that LOQTORZI significantly enhances progression-free survival and overall survival. The drug is currently available through select specialty distributors, and Coherus is committed to improving patient access and education through initiatives like NPCFacts.com, marking a notable advancement in treatment options for this aggressive cancer type.

In April 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio Inc. for $1.8 billion. This acquisition aims to significantly enhance Genmab's oncology portfolio by providing access to next-generation antibody-drug conjugates (ADCs) and proprietary technology platforms. ProfoundBio Inc. is a US-based clinical-stage biotechnology firm that develops antibody-based therapeutics for cancer patients.

Major companies operating in the nasopharyngeal carcinoma treatment market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Exelixis Inc., BeiGene Ltd., Taiho Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group, Daiichi Sankyo Company Limited, BioDiem Ltd., Coherus BioSciences Inc., Shanghai Junshi Bioscience Co Ltd., Genentech Inc., Helsinn Group, Cyclacel Pharmaceuticals Inc., Advenchen Laboratories LLC.

North America was the largest region in the nasopharyngeal carcinoma treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasopharyngeal carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the nasopharyngeal carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The nasopharyngeal carcinoma treatment market consists of revenues earned by entities by providing proton therapy, brachytherapy, external-beam radiation therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasopharyngeal carcinoma treatment market also includes sales of loqtorzi, cetuximab, gemcitabine, and cisplatin used in nasopharyngeal carcinoma treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nasopharyngeal Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nasopharyngeal carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for nasopharyngeal carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nasopharyngeal carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Nasopharyngeal Carcinoma Treatment Market Characteristics

3. Nasopharyngeal Carcinoma Treatment Market Trends And Strategies

4. Nasopharyngeal Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nasopharyngeal Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

6. Nasopharyngeal Carcinoma Treatment Market Segmentation

7. Nasopharyngeal Carcinoma Treatment Market Regional And Country Analysis

8. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market

9. China Nasopharyngeal Carcinoma Treatment Market

10. India Nasopharyngeal Carcinoma Treatment Market

11. Japan Nasopharyngeal Carcinoma Treatment Market

12. Australia Nasopharyngeal Carcinoma Treatment Market

13. Indonesia Nasopharyngeal Carcinoma Treatment Market

14. South Korea Nasopharyngeal Carcinoma Treatment Market

15. Western Europe Nasopharyngeal Carcinoma Treatment Market

16. UK Nasopharyngeal Carcinoma Treatment Market

17. Germany Nasopharyngeal Carcinoma Treatment Market

18. France Nasopharyngeal Carcinoma Treatment Market

19. Italy Nasopharyngeal Carcinoma Treatment Market

20. Spain Nasopharyngeal Carcinoma Treatment Market

21. Eastern Europe Nasopharyngeal Carcinoma Treatment Market

22. Russia Nasopharyngeal Carcinoma Treatment Market

23. North America Nasopharyngeal Carcinoma Treatment Market

24. USA Nasopharyngeal Carcinoma Treatment Market

25. Canada Nasopharyngeal Carcinoma Treatment Market

26. South America Nasopharyngeal Carcinoma Treatment Market

27. Brazil Nasopharyngeal Carcinoma Treatment Market

28. Middle East Nasopharyngeal Carcinoma Treatment Market

29. Africa Nasopharyngeal Carcinoma Treatment Market

30. Nasopharyngeal Carcinoma Treatment Market Competitive Landscape And Company Profiles

31. Nasopharyngeal Carcinoma Treatment Market Other Major And Innovative Companies

32. Global Nasopharyngeal Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nasopharyngeal Carcinoma Treatment Market

34. Recent Developments In The Nasopharyngeal Carcinoma Treatment Market

35. Nasopharyngeal Carcinoma Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기